Stocks · US
JAZZ
XNAS
Jazz Pharmaceuticals, Inc.
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-06 basis
P/E16.29x
P/B3.19x
P/S3.33x
EPS$14.49
ROE19.59%
ROA8.49%
Dividend yield0.00%
EV/EBITDA11.20x
Debt/Equity0.91
Free cash flow$1.5B
Returns and 52-week range
1W-0.41%
1M-6.25%
3M-6.79%
6M+21.18%
1Y+65.89%
YTD+33.64%
52W high$266.38
52W low$128.80
From 52W high-13.13%
Company
Peers in the same sector
| Company | Market cap | P/E | P/B | 1M |
|---|---|---|---|---|
| Medpace Holdings, Inc. Common Stock | $17.3B | 35.24 | 39.92 | +1.96% |
| 템퍼스 AI | $15.2B | — | 34.09 | +11.39% |
| Zimmer Biomet Holdings, Inc. | $17.5B | 21.65 | 1.38 | -8.56% |
| Solventum Corporation | $15.0B | 10.45 | 3.12 | -5.07% |
| Revvity, Inc. | $17.6B | 73.92 | 2.43 | +17.72% |
| Charles River Laboratories International, Inc. | $14.8B | — | 5.22 | +5.71% |
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.